Apogee Therapeutics (APGE)
NASDAQ:APGE
Want to see APGE full AI Analyst Report?
APGE Stock Chart & Stats
$92.20
-$0.82(-1.65%)
At close: 4:00 PM EST
$92.20
-$0.82(-1.65%)
Day’s Range― - ―
52-Week Range$34.34 - $95.32
Previous CloseN/A
Volume109.80K
Average Volume (3M)1.06M
Market Cap
$6.16B
Enterprise Value$5.01B
Total Cash (Recent Filing)$730.19M
Total Debt (Recent Filing)$8.85M
Price to Earnings (P/E)―
Beta1.05
Next Earnings
May 18, 2026EPS Estimate
-1.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.22
Shares Outstanding61,853,252
10 Day Avg. Volume675,701
30 Day Avg. Volume1,058,369
Financial Highlights & Ratios
PEG Ratio-0.64
Price to Book (P/B)5.07
Price to Sales (P/S)0.00
P/FCF Ratio-19.69
Enterprise Value/Market Cap0.81
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-18.04
Forecast
1Y Price Target
$122.25Price Target Upside32.59% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
EPS Forecast (FY)-4.66
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Biomarker And Mechanism AdvantageBiomarker analysis and added mechanistic targeting suggest activity beyond the typical inflammatory pathway, which could expand the addressable patient population and support potential superiority to existing treatments.
Clinical EfficacyPhase II maintenance results reported durable and deepening skin clearance and symptom improvement on multi‑month dosing, indicating a strong efficacy profile that could differentiate the drug from standard therapies.
Dosing ConvenienceMulti‑month maintenance dosing maintained clinical responses while reducing injection frequency, offering a less frequent schedule that could improve patient adherence and appeal to prescribers and payers.
Bears Say
Competitive LandscapeOther companies developing long‑acting IL‑13 therapies represent a competitive threat that could limit market share even if the drug reaches approval and commercialization.
Ocular SafetyConjunctivitis occurred relatively commonly and led to some treatment discontinuations, creating an ocular safety signal that could reduce clinician confidence and patient uptake.
Tolerability ConcernsCommon adverse events including conjunctivitis and upper respiratory infections raise tolerability concerns that may influence prescribing decisions and payer coverage.
Apogee Therapeutics News
APGE FAQ
What was Apogee Therapeutics’s price range in the past 12 months?
Apogee Therapeutics lowest stock price was $34.34 and its highest was $95.31 in the past 12 months.
What is Apogee Therapeutics’s market cap?
Apogee Therapeutics’s market cap is $6.16B.
When is Apogee Therapeutics’s upcoming earnings report date?
Apogee Therapeutics’s upcoming earnings report date is May 18, 2026 which is in 9 days.
How were Apogee Therapeutics’s earnings last quarter?
Apogee Therapeutics released its earnings results on Mar 02, 2026. The company reported -$1.03 earnings per share for the quarter, beating the consensus estimate of -$1.045 by $0.015.
Is Apogee Therapeutics overvalued?
According to Wall Street analysts Apogee Therapeutics’s price is currently Undervalued.
Does Apogee Therapeutics pay dividends?
Apogee Therapeutics does not currently pay dividends.
What is Apogee Therapeutics’s EPS estimate?
Apogee Therapeutics’s EPS estimate is -1.1.
How many shares outstanding does Apogee Therapeutics have?
Apogee Therapeutics has 61,853,252 shares outstanding.
What happened to Apogee Therapeutics’s price movement after its last earnings report?
Apogee Therapeutics reported an EPS of -$1.03 in its last earnings report, beating expectations of -$1.045. Following the earnings report the stock price went up 1.307%.
Which hedge fund is a major shareholder of Apogee Therapeutics?
Currently, no hedge funds are holding shares in APGE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Apogee Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$122.25 (32.59% Upside)
$122.25 (32.59% Upside)
Blogger Sentiment
Bullish
APGE Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 993.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.9%
Last 30 Days ▲ 2.2%
Last 30 Days ▲ 2.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
178.46%
12-Months-Change
Fundamentals
Return on Equity
-36.77%
Trailing 12-Months
Asset Growth
24.30%
Trailing 12-Months
Company Description
Apogee Therapeutics
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.
APGE Stock 12 Month Forecast
Average Price Target
$122.25
▲(32.59% Upside)
Technical Analysis
Agios Pharma
―
Ocular Therapeutix
―
Galapagos
―
Liquidia Technologies
―
IDEAYA Biosciences
―
Ownership Overview
5.96% Insiders
30.31% Mutual Funds
1.95% Other Institutional Investors
49.61% Public Companies and
Individual Investors